Victory Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Victory Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-485,173	Closed	-$3.3M	–	2872
2021 Q2	$3.3M	Sell	485,173 -1,856,832	-79%	-$15.4M	﹤0.01%	1483
2021 Q1	$24.1M	Buy	+2,342,005	New	+$25.7M	0.02%	841
2020 Q2	–	Sell	-5,898	Closed	-$28K	–	3500
2020 Q1	$28K	Buy	+5,898	New	+$34K	﹤0.01%	2992
2019 Q4	–	Sell	-2,910	Closed	-$10K	–	3483
2019 Q3	$10K	Buy	+2,910	New	+$11.6K	﹤0.01%	3276
2018 Q2	–	Sell	-610	Closed	-$14K	–	1870
2018 Q1	$14K	Buy	+610	New	+$13.5K	﹤0.01%	1802

Other funds holding JNCE

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Victory Capital Management's JNCE Position: Q3 2021 in Review

Victory Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 485,173 shares — an estimated $3.3M sold.

Victory Capital Management first reported a position in JNCE in Q1 2018 and held it in 5 quarters. The position peaked at $24.1M in Q1 2021. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

Victory Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Victory Capital Management sold 485,173 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $3.3M.
Victory Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Victory Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $24.1M in Q1 2021.
115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Victory Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.